Dataset Information


A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies.

ABSTRACT: CD20 is a cell-surface receptor expressed by healthy and neoplastic B cells and is a well-established target for biologics used to treat B-cell malignancies. Pharmacokinetic (PK) and pharmacodynamic (PD) data for the anti-CD20/CD3 T-cell-dependent bispecific antibody BTCT4465A were collected in transgenic mouse and nonhuman primate (NHP) studies. Pronounced nonlinearity in drug elimination was observed in the murine studies, and time-varying, nonlinear PK was observed in NHPs, where three empirical drug elimination terms were identified using a mixed-effects modeling approach: i) a constant nonsaturable linear clearance term (7 mL/day/kg); ii) a rapidly decaying time-varying, linear clearance term (t½  = 1.6 h); and iii) a slowly decaying time-varying, nonlinear clearance term (t½  = 4.8 days). The two time-varying drug elimination terms approximately track with time scales of B-cell depletion and T-cell migration/expansion within the central blood compartment. The mixed-effects NHP model was scaled to human and prospective clinical simulations were generated.


PROVIDER: S-EPMC5944627 | BioStudies | 2018-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5887840 | BioStudies
2019-01-01 | S-EPMC7485325 | BioStudies
2020-01-01 | S-EPMC7318214 | BioStudies
2020-01-01 | S-EPMC7529773 | BioStudies
2014-01-01 | S-EPMC4136065 | BioStudies
1000-01-01 | S-EPMC3364499 | BioStudies
2016-01-01 | S-EPMC5099539 | BioStudies
2019-01-01 | S-EPMC6768916 | BioStudies
1000-01-01 | S-EPMC4716579 | BioStudies
1000-01-01 | S-EPMC5256599 | BioStudies